File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: A young Chinese man with nephrotic syndrome due to lipoprotein glomerulopathy

TitleA young Chinese man with nephrotic syndrome due to lipoprotein glomerulopathy
Authors
KeywordsLipoprotein glomerulopathy
Apolipoprotein E
Nephrotic syndrome
Proteinuria
Statin
Issue Date2019
PublisherElsevier Inc. The Journal's web site is located at http://www.lipidjournal.com
Citation
Journal of Clinical Lipidology, 2019, v. 13 n. 2, p. 251-253 How to Cite?
AbstractLipoprotein glomerulopathy (LPG) is a rare autosomal dominant renal disease with incomplete penetrance, associated with specific protein-modifying mutations in the APOE gene. LPG is associated with poor renal prognosis, in which lipoprotein thrombi are seen in the glomerular capillaries. Dyslipidemia in LPG generally resembles type III hyperlipoproteinemia with elevated serum apolipoprotein E level. Fibrate is the most frequently reported lipid-lowering therapy in LPG as hypertriglyceridemia is common in these individuals. There are few existing case reports on effectiveness of statin monotherapy for LPG. We report a 32-year-old Chinese man who presented with nephrotic syndrome, renal impairment, severe hypercholesterolemia without hypertriglyceridemia, and hypertension. Renal biopsy confirmed lipoprotein glomerulopathy. Genetic testing confirmed APOE Kyoto mutation. Anti-hypertensive therapy, including angiotensin receptor blocker, and statin were initiated. Concomitant with normalization of lipid profile, his proteinuria markedly improved, and his renal function has remained stable up to 3 years, demonstrating sustained benefit with statin monotherapy in LPG.
Persistent Identifierhttp://hdl.handle.net/10722/272285
ISSN
2017 Impact Factor: 3.58
2015 SCImago Journal Rankings: 1.879
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLui, DTW-
dc.contributor.authorLee, ACH-
dc.contributor.authorYap, DYH-
dc.contributor.authorChan, GSW-
dc.contributor.authorTan, KCB-
dc.date.accessioned2019-07-20T10:39:17Z-
dc.date.available2019-07-20T10:39:17Z-
dc.date.issued2019-
dc.identifier.citationJournal of Clinical Lipidology, 2019, v. 13 n. 2, p. 251-253-
dc.identifier.issn1933-2874-
dc.identifier.urihttp://hdl.handle.net/10722/272285-
dc.description.abstractLipoprotein glomerulopathy (LPG) is a rare autosomal dominant renal disease with incomplete penetrance, associated with specific protein-modifying mutations in the APOE gene. LPG is associated with poor renal prognosis, in which lipoprotein thrombi are seen in the glomerular capillaries. Dyslipidemia in LPG generally resembles type III hyperlipoproteinemia with elevated serum apolipoprotein E level. Fibrate is the most frequently reported lipid-lowering therapy in LPG as hypertriglyceridemia is common in these individuals. There are few existing case reports on effectiveness of statin monotherapy for LPG. We report a 32-year-old Chinese man who presented with nephrotic syndrome, renal impairment, severe hypercholesterolemia without hypertriglyceridemia, and hypertension. Renal biopsy confirmed lipoprotein glomerulopathy. Genetic testing confirmed APOE Kyoto mutation. Anti-hypertensive therapy, including angiotensin receptor blocker, and statin were initiated. Concomitant with normalization of lipid profile, his proteinuria markedly improved, and his renal function has remained stable up to 3 years, demonstrating sustained benefit with statin monotherapy in LPG.-
dc.languageeng-
dc.publisherElsevier Inc. The Journal's web site is located at http://www.lipidjournal.com-
dc.relation.ispartofJournal of Clinical Lipidology-
dc.subjectLipoprotein glomerulopathy-
dc.subjectApolipoprotein E-
dc.subjectNephrotic syndrome-
dc.subjectProteinuria-
dc.subjectStatin-
dc.titleA young Chinese man with nephrotic syndrome due to lipoprotein glomerulopathy-
dc.typeArticle-
dc.identifier.emailYap, DYH: desmondy@hku.hk-
dc.identifier.emailTan, KCB: kcbtan@hkucc.hku.hk-
dc.identifier.authorityYap, DYH=rp01607-
dc.identifier.authorityTan, KCB=rp00402-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.jacl.2018.12.004-
dc.identifier.pmid30685233-
dc.identifier.scopuseid_2-s2.0-85060340719-
dc.identifier.hkuros299531-
dc.identifier.volume13-
dc.identifier.issue2-
dc.identifier.spage251-
dc.identifier.epage253-
dc.identifier.isiWOS:000468125200005-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats